Novel photosensitizers demonstrate tunable intersystem crossing, enhancing efficacy in optobiology and therapy.
A compact photosensitizer platform has been developed to enable precise and tunable control over intersystem crossing (ISC) without the use of heavy atoms. The tetrad-based molecular architecture incorporates a simple electron-withdrawing substituent, allowing ISC to be switched OFF and the photosensitizer to remain inactive until reactivated. This design achieves an exceptionally long excited-state lifetime of 142 μs, facilitating low-dose operation with phototoxic efficacy that is virtually independent of oxygen concentration. The heavy-atom-free structure minimizes dark toxicity and enhances intracellular distribution. By overcoming key limitations of conventional photosensitizers─such as reliance on heavy atoms, poor selectivity, and lack of spatiotemporal control─the platform establishes a universal scaffold for biomedical applications. Beyond photodynamic therapy, the system provides a foundational molecular tool for optobiology, enabling light-mediated regulation of biological functions with high precision. These features position the photosensitizer as a versatile agent for advancing therapeutic strategies and light-regulated life sciences.
No takes yet. Share an insight, caveat, or question.
Maki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: